Total raised
$25.3M
Last: Series A 2024-06
Stage
Series A
Founded
2018
Headcount
46
HQ
Tel Aviv-Yafo
Sector
Health Tech & Life Sciences
About
NeuroKaire (formerly Genetika+) is developing a personalized medical testing tool to better treat depression by helping physicians find the best drug therapy for their patients. The NeuroKaire test predicts the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.
Funding history · 2 rounds · $25.3M total
2024-06
Series A
$10.0M
2021-09
Series A
$10.0M
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesDigital HealthcareDigital Medical DiagnosticsMedical Decision Support
Technologies
Artificial IntelligenceMachine Learning
Target customers
Healthcare & Life SciencesHealthcarePatientsProvidersLife SciencesPharmaceuticals
Business model
B2B2CB2B
Highlights
1 PatentsVerified
Tags
clinical-trialsneurologygenetic-engineeringpharma-companiesdeep-learningmental-healthmachine-learningdigital-healthcaremedicationdoctorspersonalizationtestingartificial-intelligenceclinicshealthcare-providerspatientsneurosciencehospitalspsychiatrydecision-support